Keyword search (4,163 papers available)

"Gauthier S" Authored Publications:

Title Authors PubMed ID
1 Impact of a national dementia research consortium: The Canadian Consortium on Neurodegeneration in Aging (CCNA) Chertkow H; Phillips N; Rockwood K; Anderson N; Andrew MK; Bartha R; Beaudoin C; Bélanger N; Bellec P; Belleville S; Bergman H; Best S; Bethell J; Bherer L; Black S; Borrie M; Camicioli R; Carrier J; Cashman N; Chan S; Crowshoe L; Cuello C; Cynader M; Dang-Vu T; Das S; Dixon RA; Ducharme S; Einstein G; Evans AC; Fahnestock M; Feldman H; Ferland G; Finger E; Fisk JD; Fogarty J; Fon E; Gan-Or Z; Gauthier S; Greenwood C; Henri-Bellemare C; Herrmann N; Hogan DB; Hsiung R; Itzhak I; Jacklin K; Lanctôt K; Lim A; MacKenzie I; Masellis M; Maxwell C; McAiney C; McGilton K; McLaurin J; Mihailidis A; Mohades Z; Montero-Odasso M; Morgan D; Naglie G; Nygaard H; O' Connell M; Petersen R; Pilon R; Rajah MN; Rapoport M; Roach P; Robillard JM; Rogaeva E; Rosa-Neto P; Rylett J; Sadavoy J; St George-Hyslop P; Seitz D; Smith E; Stefanovic B; Vedel I; Walker JD; Wellington C; Whitehead V; Wittich W; 39636028
HKAP
2 Comparison of Radiologists and Deep Learning for US Grading of Hepatic Steatosis Vianna P; Calce SI; Boustros P; Larocque-Rigney C; Patry-Beaudoin L; Luo YH; Aslan E; Marinos J; Alamri TM; Vu KN; Murphy-Lavallée J; Billiard JS; Montagnon E; Li H; Kadoury S; Nguyen BN; Gauthier S; Therien B; Rish I; Belilovsky E; Wolf G; Chassé M; Cloutier G; Tang A; 37787678
ENCS
3 CCCDTD5: Clinical role of neuroimaging and liquid biomarkers in patients with cognitive impairment Brisson M; Brodeur C; Létourneau-Guillon L; Masellis M; Stoessl J; Tamm A; Zukotynski K; Ismail Z; Gauthier S; Rosa-Neto P; Soucy JP; 33532543
PERFORM
4 Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia. Ismail Z, Black SE, Camicioli R, Chertkow H, Herrmann N, Laforce R, Montero-Odasso M, Rockwood K, Rosa-Neto P, Seitz D, Sivananthan S, Smith EE, Soucy JP, Vedel I, Gauthier S, CCCDTD5 participants 32725777
PERFORM
5 Topographical distribution of Aβ predicts progression to dementia in Aβ positive mild cognitive impairment Pascoal TA, Therriault J, Mathotaarachchi S, Kang MS, Shin M, Benedet AL, Chamoun M, Tissot C, Lussier F, Mohaddes S, Soucy JP, Massarweh G, Gauthier S, Rosa-Neto P, 32582834
PERFORM
6 Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer's disease. Hadoux X, Hui F, Lim JKH, Masters CL, Pébay A, Chevalier S, Ha J, Loi S, Fowler CJ, Rowe C, Villemagne VL, Taylor EN, Fluke C, Soucy JP, Lesage F, Sylvestre JP, Rosa-Neto P, Mathotaarachchi S, Gauthier S, Nasreddine ZS, Arbour JD, Rhéaume MA, Beaulieu S, Dirani M, Nguyen CTO, Bui BV, Williamson R, Crowston JG, van Wijngaarden P 31530809
PERFORM
7 The Comprehensive Assessment of Neurodegeneration and Dementia: Canadian Cohort Study. Chertkow H, Borrie M, Whitehead V, Black SE, Feldman HH, Gauthier S, Hogan DB, Masellis M, McGilton K, Rockwood K, Tierney MC, Andrew M, Hsiung GR, Camicioli R, Smith EE, Fogarty J, Lindsay J, Best S, Evans A, Das S, Mohaddes Z, Pilon R, Poirier J, Phillips NA, MacNamara E, Dixon RA, Duchesne S, MacKenzie I, Rylett RJ 31309917
PSYCHOLOGY
8 Brain perfusion during rapid-eye-movement sleep successfully identifies amnestic mild cognitive impairment. Brayet P, Petit D, Baril AA, Gosselin N, Gagnon JF, Soucy JP, Gauthier S, Kergoat MJ, Carrier J, Rouleau I, Montplaisir J 28522082
PERFORM
9 Quantification of brain cholinergic denervation in Alzheimer's disease using PET imaging with [18F]-FEOBV. Aghourian M, Legault-Denis C, Soucy JP, Rosa-Neto P, Gauthier S, Kostikov A, Gravel P, Bédard MA 28894304
PERFORM
10 Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer's disease. Pascoal TA, Mathotaarachchi S, Shin M, Park AY, Mohades S, Benedet AL, Kang MS, Massarweh G, Soucy JP, Gauthier S, Rosa-Neto P, Alzheimer’s Disease Neuroimaging Initiative 29396637
PERFORM

 

Title:Quantification of brain cholinergic denervation in Alzheimer's disease using PET imaging with [18F]-FEOBV.
Authors:Aghourian M,  Legault-Denis C,  Soucy JP,  Rosa-Neto P,  Gauthier S,  Kostikov A,  Gravel P,  Bédard MA
Link:https://www.ncbi.nlm.nih.gov/pubmed/28894304?dopt=Abstract
DOI:10.1038/mp.2017.183
Publication:Molecular psychiatry
Keywords:
PMID:28894304 Category:Mol Psychiatry Date Added:2019-04-15
Dept Affiliation: PERFORM
1 Université du Québec à Montréal (UQAM), Cognitive Pharmacology Research Unit, Montreal, QC, Canada.
2 McConnell Brain Imaging Centre, Montreal Neurological Institute, Montreal, QC, Canada.
3 McGill Centre for Studies in Aging, Douglas Mental Health University Institute, Verdun, QC, Canada.
4 Department of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada.
5 PERFORM Centre, Concordia University, Montreal, QC, Canada.

Description:

Quantification of brain cholinergic denervation in Alzheimer's disease using PET imaging with [18F]-FEOBV.

Mol Psychiatry. 2017 11;22(11):1531-1538

Authors: Aghourian M, Legault-Denis C, Soucy JP, Rosa-Neto P, Gauthier S, Kostikov A, Gravel P, Bédard MA

Abstract

18F-fluoroethoxybenzovesamicol (FEOBV) is a new PET radiotracer that binds to the vesicular acetylcholine transporter. In both animals and healthy humans, FEOBV was found sensitive and reliable to characterize presynaptic cholinergic nerve terminals in the brain. It has been used here for we believe the first time in patients with Alzheimer's disease (AD) to quantify brain cholinergic losses. The sample included 12 participants evenly divided in healthy subjects and patients with AD, all assessed with the Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) cognitive scales. Every participant underwent three consecutive PET imaging sessions with (1) the FEOBV as a tracer of the cholinergic terminals, (2) the 18F-NAV4694 (NAV) as an amyloid-beta tracer, and (3) the 18F-Fluorodeoxyglucose (FDG) as a brain metabolism agent. Standardized uptake value ratios (SUVRs) were computed for each tracer, and compared between the two groups using voxel wise t-tests. Correlations were also computed between each tracer and the cognitive scales, as well as between FEOBV and the two other radiotracers. Results showed major reductions of FEOBV uptake in multiple cortical areas that were evident in each AD subject, and in the AD group as a whole when compared to the control group. FDG and NAV were also able to distinguish the two groups, but with lower sensitivity than FEOBV. FEOBV uptake values were positively correlated with FDG in numerous cortical areas, and negatively correlated with NAV in some restricted areas. The MMSE and MoCA cognitive scales were found to correlate significantly with FEOBV and with FDG, but not with NAV. We concluded that PET imaging with FEOBV is more sensitive than either FDG or NAV to distinguish AD patients from control subjects, and may be useful to quantify disease severity. FEOBV can be used to assess cholinergic degeneration in human, and may represent an excellent biomarker for AD.

PMID: 28894304 [PubMed - indexed for MEDLINE]




BookR developed by Sriram Narayanan
for the Concordia University School of Health
Copyright © 2011-2026
Cookie settings
Concordia University